153. The first humanized monoclonal antibody approved by the US-FDA for targeted treatment of breast cancer
was:
(1) Trastuzumab
(2) Paliviuzmab
(3) Gemtuzumab
(4) Natalizumab
The First Humanized Monoclonal Antibody Approved for Breast Cancer Treatment: Trastuzumab
Monoclonal antibodies (mAbs) have revolutionized the way we treat cancers, offering targeted therapies that are more effective and less toxic than traditional treatments. One of the most significant advancements in cancer therapy was the approval of Trastuzumab, the first humanized monoclonal antibody to be approved by the US-FDA for the treatment of HER2-positive breast cancer.
What is Trastuzumab?
Trastuzumab, sold under the brand name Herceptin, is a humanized monoclonal antibody designed to specifically target the HER2 receptor, which is overexpressed in some breast cancer cells. The HER2 gene, responsible for encoding the human epidermal growth factor receptor 2 (HER2), is present in normal cells, but in HER2-positive breast cancer, this gene is amplified, causing rapid and uncontrolled cell growth.
Trastuzumab binds to these HER2 receptors on the surface of cancer cells, blocking the receptor’s signals that promote tumor growth. Additionally, it triggers the immune system to destroy the cancer cells, making it an effective treatment for patients with this aggressive form of breast cancer.
Approval and Impact
Trastuzumab was approved by the US FDA in 1998, marking a milestone in breast cancer therapy. Prior to its approval, treatment options for HER2-positive breast cancer were limited, and the prognosis for patients with this subtype was poor. The introduction of Trastuzumab provided a targeted therapy, meaning it could specifically attack the cancerous cells without damaging healthy tissue as much as chemotherapy does.
Trastuzumab has significantly improved survival rates for those diagnosed with HER2-positive breast cancer. Studies have shown that its use, either alone or in combination with chemotherapy, can reduce the recurrence of cancer, improving both survival and quality of life for patients.
How Does Trastuzumab Work?
Trastuzumab works through several mechanisms:
-
Blocking HER2 Signaling: It prevents the HER2 receptors from sending growth signals to cancer cells, inhibiting their proliferation.
-
Antibody-Dependent Cellular Cytotoxicity (ADCC): It stimulates the immune system to recognize and kill HER2-positive cancer cells.
-
Inhibition of Tumor Growth: By blocking HER2 signaling, trastuzumab slows down the growth and spread of the tumor.
Other Related Monoclonal Antibodies
While Trastuzumab was the first FDA-approved humanized monoclonal antibody for breast cancer, there are other monoclonal antibodies used in cancer treatment. However, none of them specifically target HER2 like trastuzumab. Some examples include:
-
Palivizumab: Used for respiratory syncytial virus (RSV) prevention, not for cancer treatment.
-
Gemtuzumab: Used for treating acute myeloid leukemia (AML), not breast cancer.
-
Natalizumab: Used for treating multiple sclerosis and Crohn’s disease, not breast cancer.
Conclusion
Trastuzumab, as the first humanized monoclonal antibody for breast cancer, has made a profound impact on the treatment landscape for HER2-positive breast cancer. It has improved survival rates and quality of life for many patients, and its success has paved the way for other targeted therapies in oncology. Today, trastuzumab remains a cornerstone in the treatment of breast cancer, offering hope for many who were once facing limited options
